This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Neptune Dismisses Aker's Inaccurate Allegations About Its New Patent

LAVAL, Quebec, Oct. 3, 2012 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. (" Neptune") (Nasdaq:NEPT) (TSX:NTB), the pioneer in the krill oil industry, which holds a vast international patent estate on krill oil compositions and methods of use, reiterates that it achieved its latest patent grant, a continuation patent numbered US 8,278,351 (the "Continuation Patent"), after a thorough examination process.

Neptune firmly denies the allegation made by Aker in its press release of October 2, 2012, that Neptune failed to disclose to the U.S. Patent & Trademark Office (the "USPTO") certain record evidence from the re-examination of the '348 patent, another Neptune patent to which the Continuation Patent is related. Not only did Neptune submit all record evidence from this re-examination, but it also submitted approximately 200 references that the USPTO's Examiner reviewed during examination, including all of the references that Aker put forth in requesting re-examination of the '348 patent. Further, as the USPTO record explicitly shows, the USPTO's Examiner was fully aware of the re-examination and considered it before allowing the present patent.

"Aker is now facing an action for infringement of a patent that reads directly on its krill oil products and that was allowed over extensive references, including all of the references relied upon by Aker in requesting re-examination of a related Neptune patent," said Benoit Huart, General Counsel of Neptune. "Aker's baseless allegation that Neptune withheld evidence from the USPTO is merely its latest ill-conceived attempt to deflect attention from its infringement of Neptune's patents and diminish Neptune's status as the first and leading innovator in the krill oil industry."

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $118.00 1.10%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs